| Trial ID: | L3926 |
| Source ID: | NCT02040246
|
| Associated Drug: |
Repaglinide
|
| Title: |
Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Repaglinide|DRUG: Metformin
|
| Outcome Measures: |
Primary: HbA1c change from baseline, week 12 |
|
| Sponsor/Collaborators: |
Sponsor: RenJi Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
107
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2009-02
|
| Completion Date: |
2014-01
|
| Results First Posted: |
|
| Last Update Posted: |
2014-01-20
|
| Locations: |
Renji Hospital, Shanghai, Shanghai, 200127, China|Renji Hospital, Shanghai, 200127, China
|
| URL: |
https://clinicaltrials.gov/show/NCT02040246
|
